Although next-generation sequencing assays are routinely carried out using samples from cancer trials, the sequencing data are not always of the required quality. There is a need to evaluate the performance of tissue collection sites and provide feedback about the quality of next-generation sequencing data. This study used a modeling approach based on whole exome sequencing quality control (QC) metrics to evaluate the relative performance of sites participating in the Bristol Myers Squibb Immuno-Oncology clinical trials sample collection. We identified several events for the sample swap. Overall, most sites performed well and few showed poor performance. These findings can increase awareness of sample failure and improve the quality of samples.

中文翻译：

---

使用全外显子组测序指标对样本采集位点的性能进行建模。

尽管下一代测序分析通常使用来自癌症试验的样本进行，但测序数据并不总是具有所需的质量。需要评估组织收集站点的性能并提供有关下一代测序数据质量的反馈。本研究使用基于全外显子组测序质量控制 (QC) 指标的建模方法来评估参与百时美施贵宝免疫肿瘤学临床试验样本收集的站点的相对性能。我们为样本交换确定了几个事件。总体而言，大多数网站表现良好，少数网站表现不佳。这些发现可以提高对样本失败的认识并提高样本质量。